Isofol Medical Encouraging progress
The Q2 operating loss of cSEK36m was in line with our estimate of cSEK37.5m. In our view, the main event in Q2 was the encouraging data reported from the extension of the phase I/IIa trial with a best overall response rate of 58%. Furthermore, the company strengthened its patent portfolio with two clinical use patents. Lastly, three new members were elected to the board of directors. We reiterate our fair value of SEK18–49.
DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.